480 Biomedical
5 articles about 480 Biomedical
-
Watertown, Massachusetts-based Lyra Therapeutics closed a Series B financing worth $29.5 million. Its lead compound is LYR-210, which the company plans to take into a Phase II clinical trial for chronic rhinosinusitis
-
Arsenal Medical and 480 Biomedical Bank $26.5 Million in Combined Funding
6/1/2015
-
480 Biomedical Awarded $1 Million Phase II NHLBI Contract To Advance Bioresorbable Scaffold For Pediatric Pulmonary Artery Stenosis
7/9/2014
-
480 Biomedical Announces Initial Observations From OCT Sub-Study of the STANCE Trial Evaluating the First Self-Expanding Bioresorbable Scaffold for Superficial Femoral Artery Disease
10/10/2012
-
480 Biomedical Announces First Human Trial of the StanzaTM Bioresorbable Scaffold in Peripheral Artery Disease
4/16/2012